Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3
Citations Over TimeTop 1% of 2013 papers
Abstract
The sirtuins SIRT1, SIRT2, and SIRT3 are NAD(+) dependent deacetylases that are considered potential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders. Encoded library technology (ELT) was used to affinity screen a 1.2 million heterocycle enriched library of DNA encoded small molecules, which identified pan-inhibitors of SIRT1/2/3 with nanomolar potency (e.g., 11c: IC50 = 3.6, 2.7, and 4.0 nM for SIRT1, SIRT2, and SIRT3, respectively). Subsequent SAR studies to improve physiochemical properties identified the potent drug like analogues 28 and 31. Crystallographic studies of 11c, 28, and 31 bound in the SIRT3 active site revealed that the common carboxamide binds in the nicotinamide C-pocket and the aliphatic portions of the inhibitors extend through the substrate channel, explaining the observable SAR. These pan SIRT1/2/3 inhibitors, representing a novel chemotype, are significantly more potent than currently available inhibitors, which makes them valuable tools for sirtuin research.
Related Papers
- → Shedding light on structure, function and regulation of human sirtuins: a comprehensive review(2022)48 cited
- → Molecular Dynamics Simulation Reveals New Pocket for the Design of Novel Amino Acid Coupled Sirt1 Selective Inhibitor(2020)3 cited
- → Sirtuins as Potential Drug Targets for Metabolic Diseases(2011)
- Biochemical and structural studies on the mitochondrial Sirtuins 4 and 5(2018)
- → Effect of Nutritional Stress on the Expression of Sirtuin Gene Family(2020)